Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Thoracic 4CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 125Carboplatin 123Pemetrexed 102Cisplatin 77Paclitaxel 59osimertinib 52Nivolumab 52Docetaxel 52durvalumab 46Specimen Handling 40Gemcitabine 36Magnetic Resonance Spectroscopy 35Radiosurgery 27atezolizumab 25Cetuximab 25130-nm albumin-bound paclitaxel 25Ipilimumab 22Drug Therapy 21cemiplimab 20Radiotherapy 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Biopsy 12lazertinib 11Radiation 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × lorlatinib × 90 days × Clear all
NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Pfizer

Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
56 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Pfizer

Completed
73 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡